Sage/Biogen See Big Potential Market For Zuranolone In PPD
SKYLARK Meets Primary, Key Secondary Endpoints
The companies reported positive Phase III data in postpartum depression, a market opportunity of up to half a million women in the US with a condition that remains underdiagnosed.
